Eagle Pharmaceuticals sees 2023 adjusted EPS $4.20-$4.53, consensus $4.49

Sees Adjusted EBITDA of $74.0-$80.0 million; Adjusted non-GAAP R&D expense of $41.0-$45.0 million; Adjusted non-GAAP SG&A expense of $86.0-$90.0 million.